The comparison of muscle strength and short-term endurance in the different periods of type 2 diabetes

Journal of Diabetes & Metabolic Disorders

Mohammad R Mohajeri Tehrani¹  Farid Bahrpeyma²  Boshra Hatef² 

[1] Endocrinology and Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Iran;Department of physical therapy, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran

关键词: Knee flexor;    Knee extensor;    short-term endurance;    Strength;    Isokinetic;    Type 2 diabetes mellitus;   

Others  :  806297
DOI  :  10.1186/2251-6581-13-22

 received in 2013-06-20, accepted in 2013-12-19,  发布年份 2014

【 摘 要 】

Background

Patients with type 2 diabetes (T2DM) are subjected to reduction in the quality and oxidative capacity of muscles. The effect of duration of diabetes on the muscle endurance response is not clear and strength as well.

Objective

The aim of this study was the assessment of strength and endurance of knee extensor and flexor in the patients with T2DM < 10 and T2DM > 10 years in comparison with age, sex, BMI, ABI and PAI-matched health control subjects.

Methods

Isometric maximal peak torque (MPT) of knee extensor and flexor before and after 40 isokinetic repetitions with velocity of 150 degree/s were recorded in 18 patients with T2DM < 10 Y , 12 patients with T2DM > 10 Y and 20 matched health control (HC) groups.

Results

Both diabetic patient groups had significant lower isometric and isotonic knee extensor and flexor strength than HC. The endurance indices indicated that whereas the isometric MPT of flexor movement was reduced after isokinetic protocol in the both patient groups in comparison with HC, the less decline was seen in the isotonic torque and work during isokinetic protocol in the T2DM > 10 Y group in comparison with two other groups. The HbA1c and FPG were significantly correlated with strength not with endurance indices.

Conclusions

It seems the progression of diabetes accompanied with vascular, neural and muscular deficits activate, some adaptive and compensatory processes which can maintain muscle performance.

【 授权许可】

   
2014 Hatef et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Andersen H: Muscular endurance in long-term IDDM patients. Diabetes Care 1998, 21:604-609.
• [2]Andersen H, Nielsen S, Mogensen CE, Jakobsen J: Muscle strength in type 2 diabetes. Diabetes 2004, 53:1543-1548.
• [3]Andersen H, Poulsen PL, Mogensen CE, Jakobsen J: Isokinetic muscle strength in long-term IDDM patients in relation to diabetic complications. Diabetes 1996, 45:440-445.
• [4]Bokan V: Muscle weakness and other late complications of diabetic polyneuropathy. Acta Clin Croat 2011, 50:351-355.
• [5]Halvatsiotis P, Short KR, Bigelow M, Nair KS: Synthesis rate of muscle proteins, muscle functions, and amino acid kinetics in type 2 diabetes. Diabetes 2002, 51:2395-2404.
• [6]IJzerman TH SNC, Melai T, Meijer K, Willems PJ, Savelberg HH: Lower extremity muscle strength is reduced in people with type 2 diabetes, with and without polyneuropathy, and is associated with impaired mobility and reduced quality of life. Diabetes Res Clin Pract 2012, 95:345-351.
• [7]Park SW, Goodpaster BH, Strotmeyer ES, de Rekeneire N, Harris TB, Schwartz AV, Tylavsky FA, Newman AB: Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes 2006, 55:1813-1818.
• [8]Roden M: Muscle triglycerides and mitochondrial function: possible mechanisms for the development of type 2 diabetes. Int J Obes (Lond) 2005, 29(Suppl 2):S111-115.
• [9]Sayer AA, Dennison EM, Syddall HE, Gilbody HJ, Phillips DI, Cooper C: Type 2 diabetes, muscle strength, and impaired physical function: the tip of the iceberg? Diabetes Care 2005, 28:2541-2542.
• [10]Fritschi C, Quinn L: Fatigue in patients with diabetes: a review. J Psychosom Res 2010, 69:33-41.
• [11]Zierath JR, Hawley JA: Skeletal muscle fiber type: influence on contractile and metabolic properties. PLoS Biol 2004, 2:e348.
• [12]John AB, Silvio B: Sarcopenia, Sarcopenic Obesity and Insulin Resistance. 2011.
• [13]MÅrin P, Andersson B, Krotkiewski M, Björntorp P: Muscle fiber composition and capillary density in women and men with NIDDM. Diabetes Care 1994, 17:382-386.
• [14]Oberbach A, Bossenz Y, Lehmann S, Niebauer J, Adams V, Paschke R, Schön MR, Blüher M, Punkt K: Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes. Diabetes Care 2006, 29:895-900.
• [15]Murakami S, Fujita N, Kondo H, Takeda I, Momota R, Ohtsuka A, Fujino H: Abnormalities in the fiber composition and capillary architecture in the soleus muscle of type 2 diabetic Goto-Kakizaki rats. ScientificWorldJournal 2012, 2012:680189.
• [16]Rabol R, Boushel R, Dela F: Mitochondrial oxidative function and type 2 diabetes. Appl Physiol Nutr Metab 2006, 31:675-683.
• [17]Gaster M, Staehr P, Beck-Nielsen H, Schrøder HD, Handberg A: GLUT4 is reduced in slow muscle fibers of type 2 diabetic patients: is insulin resistance in type 2 diabetes a slow, type 1 fiber disease? Diabetes 2001, 50:1324-1329.
• [18]Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, Chasan-Taber L, Albright AL, Braun B: Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care 2010, 33:e147-167.
• [19]Ena J, Lozano T, Verdu G, Argente CR, Gonzalez VL: Accuracy of ankle-brachial index obtained by automated blood pressure measuring devices in patients with diabetes mellitus. Diabetes Res Clin Pract 2011, 92:329-336.
• [20]Smith KA, Gallagher M, Hays AE, Goss FL, Robertson R: Development of the physical activity index as a measure of total activity load and total kilocalorie expenditure during submaximal walking. J Phys Act Health 2012, 9:757-764.
• [21]Al-Zahrani E, Gunasekaran C, Callaghan M, Gaydecki P, Benitez D, Oldham J: Within-day and between-days reliability of quadriceps isometric muscle fatigue using mechanomyography on healthy subjects. J Electromyogr Kinesiol 2009, 19:695-703.
• [22]Andreassen CS, Jakobsen J, Andersen H: Muscle weakness: a progressive late complication in diabetic distal symmetric polyneuropathy. Diabetes 2006, 55:806-812.
• [23]Hawley JA, Zierath JR: Physical activity and type 2 diabetes: therapeutic effects and mechanisms of action. 1th edition edn. In Human Kinetics. Ill, USA: Champaign; 2008.
• [24]Lindle RS, Metter EJ, Lynch NA, Fleg JL, Fozard JL, Tobin J, Roy TA, Hurley BF: Age and gender comparisons of muscle strength in 654 women and men aged 20-93 yr. J Appl Physiol 1997, 83:1581-1587.
• [25]Harbo T, Brincks J, Andersen H: Maximal isokinetic and isometric muscle strength of major muscle groups related to age, body mass, height, and sex in 178 healthy subjects. Eur J Appl Physiol 2012, 112:267-275.
• [26]Jones EJ, Bishop PA, Woods AK, Green JM: Cross-sectional area and muscular strength: a brief review. Sports Med 2008, 38:987-994.
• [27]Park SW, Goodpaster BH, Strotmeyer ES, Kuller LH, Broudeau R, Kammerer C, de Rekeneire N, Harris TB, Schwartz AV, Tylavsky FA, et al.: Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care 2007, 30:1507-1512.
• [28]Sreekumar RNK: Skeletal muscle mitochondrial dysfunction & diabetes. Indian J Med Res 2007, 123:339-410.
• [29]Lanza IR, Nair KS: Muscle mitochondrial changes with aging and exercise. Am J Clin Nutr 2009, 89:467S-471S.
• [30]He J, Watkins S, Kelley DE: Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity. Diabetes 2001, 50:817-823.
• [31]Chattopadhyay M, GuhaThakurta I, Behera P, Ranjan KR, Khanna M, Mukhopadhyay S, Chakrabarti S: Mitochondrial bioenergetics is not impaired in nonobese subjects with type 2 diabetes mellitus. Metabolism 2011, 60:1702-1710.
• [32]Andreassen CS, Jakobsen J, Flyvbjerg A, Andersen H: Expression of neurotrophic factors in diabetic muscle–relation to neuropathy and muscle strength. Brain 2009, 132:2724-2733.
• [33]Onishi H, Yagi R, Oyama M, Akasaka K, Ihashi K, Handa Y: EMG-angle relationship of the hamstring muscles during maximum knee flexion. J Electromyogr Kinesiol 2002, 12:399-406.
• [34]Perkins BA, Bril V: Diabetic neuropathy: a review emphasizing diagnostic methods. Clin Neurophysiol 2003, 114:1167-1175.
• [35]Lexell JAN, Henriksson-LarsÉN K, SjÖStrÖM M: Distribution of different fibre types in human skeletal muscles 2. A study of cross-sections of whole m. vastus lateralis. Acta Physiol Scand 1983, 117(1):115-22.
• [36]Garrett WE Jr, Califf JC, Bassett FH 3rd: Histochemical correlates of hamstring injuries. Am J Sports Med 1984, 12:98-103.
• [37]Dahmane R, Djordjevic S, Smerdu V: Adaptive potential of human biceps femoris muscle demonstrated by histochemical, immunohistochemical and mechanomyographical methods. Med Biol Eng Comput 2006, 44:999-1006.
• [38]Spriet LL: Anaerobic metabolism in human skeletal muscle during short-term, intense activity. Can J Physiol Pharmacol 1992, 70:157-165.
• [39]Huang E-J, Kuo W-W, Chen Y-J, Chen T-H, Chang M-H, Lu M-C, Tzang B-S, Hsu H-H, Huang C-Y, Lee S-D: Homocysteine and other biochemical parameters in type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. Clin Chim Acta 2006, 366:293-298.
• [40]Mongraw-Chaffin ML, Matsushita K, Brancati FL, Astor BC, Coresh J, Crawford SO, Schmidt MI, Hoogeveen RC, Ballantyne CM, Young JH: Diabetes medication use and blood lactate level among participants with type 2 diabetes: the atherosclerosis risk in communities carotid MRI study. PLoS One 2012, 7:e51237.
• [41]Greenhaff PL, Nevill ME, Soderlund K, Bodin K, Boobis LH, Williams C, Hultman E: The metabolic responses of human type I and II muscle fibres during maximal treadmill sprinting. J Physiol 1994, 478(Pt 1):149-155.
• [42]Nyholm B, Qu Z, Kaal A, Pedersen SB, Gravholt CH, Andersen JL, Saltin B, Schmitz O: Evidence of an increased number of type IIb muscle fibers in insulin-resistant first-degree relatives of patients with NIDDM. Diabetes 1997, 46:1822-1828.
• [43]Gaster M, Poulsen P, Handberg A, Schrøder HD, Beck-Nielsen H: Direct evidence of fiber type-dependent GLUT-4 expression in human skeletal muscle. Am J Physiol - Endocrinol Metab 2000, 278:E910-E916.
• [44]Schiaffino S, Reggiani C: Fiber types in mammalian skeletal muscles. Physiol Rev 2011, 91:1447-1531.
• [45]Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M: Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995, 333:89-94.
• [46]Cameron NE, Cotter MA: The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Rev 1994, 10:189-224.
• [47]Fanzani A, Conraads VM, Penna F, Martinet W: Molecular and cellular mechanisms of skeletal muscle atrophy: an update. J Cachexia Sarcopenia Muscle 2012, 3:163-179.
• [48]Aydeniz A, Gursoy S, Guney E: Which musculoskeletal complications are most frequently seen in type 2 diabetes mellitus? J Int Med Res 2008, 36:505-511.
• [49]De Feyter HM, van den Broek NM, Praet SF, Nicolay K, van Loon LJ, Prompers JJ: Early or advanced stage type 2 diabetes is not accompanied by in vivo skeletal muscle mitochondrial dysfunction. Eur J Endocrinol 2008, 158:643-653.
• [50]Schrauwen-Hinderling VB, Kooi ME, Hesselink MK, Jeneson JA, Backes WH, van Echteld CJ, van Engelshoven JM, Mensink M, Schrauwen P: Impaired in vivo mitochondrial function but similar intramyocellular lipid content in patients with type 2 diabetes mellitus and BMI-matched control subjects. Diabetologia 2007, 50:113-120.